Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.

ASX Announcements (7d)

-

Twitter Mentions (7d)

0+

AFR Articles (7d)

-

News Articles (7d)

4+
Subject
TLX Ann: Release of Shares from Voluntary Escrow

TLX Ann: IPAX-1 Presentation at Congress of Neurological Surgeons

TLX Ann: Cleansing Notice under S708A Corporations Act

TLX Ann: Appendix 3Y - Change of Directors Interest Notice - McCann

TLX Ann: Appendix 3Y - Change of Directors Interest Notice - Nelson

TLX Ann: Application for quotation of securities - TLX

TLX Ann: $12.1M R&D Tax Refund, Overseas Finding Increased to $139M

TLX Ann: FDA Extends New Drug Application Review Period for Illuccix

TLX Ann: Telix Supporting Amgen PSMA-Targeting Therapy Trial

TLX Ann: NCCN Guidelines updated to include PSMA-PET Imaging

TLX Ann: FDA Approves Phase II Kidney Cancer Therapy Study

TLX Ann: Telix and Radius sign Distribution Agreement for Italy

TLX Ann: Japanese Prostate Cancer Imaging Study Completes Enrolment

TLX Ann: Change in substantial holding

TLX Ann: Collaboration with Lightpoint Medical on Radioguided Surgery

TLX Ann: Results Presentation and Shareholder Update 1H 2021

TLX Ann: App 4D and Report for Half-Year Ended 30 June 2021

TLX Ann: GenesisCare Collaboration Expands Prostate Cancer Activity

TLX Ann: Telix and Merck pan-cancer clinical collaboration

TLX Ann: Two studies explore TLX assets in Breast Cancer Theranostics

TLX Ann: TLX66 in Phase II Academic Study of Pediatric Leukemia

TLX Ann: Telix H1 2021 Results and Company Update Conference Call

TLX Ann: 1st Patient Dosed in CUPID study of TLX592

TLX Ann: Telix Seneffe Production Facility - Progress Update

TLX Ann: App 4C and Activities Report for June 2021 Quarter

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update

TLX Ann: Ky Williamson to lead corporate communications and IR

TLX Ann: Change in substantial holding

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Cleansing Notice - issue of shares upon exercise of options

TLX Ann: 1st patient dosed in TLX250-CDx study in Bladder Cancer

TLX Ann: TLX101 for Glioblastoma Therapy - Clinical Trial Update

TLX Ann: Update on FDA New Drug Application Review for Illuccix

TLX Ann: Telix and ATS $1.56M Eurostars Grant for Alpha Therapy

TLX Ann: US Co-Promotion with EZAG for Prostate Cancer Imaging

TLX Ann: Presentation to Jefferies Healthcare Conference

TLX Ann: Shareholder Update - TRALA Trial of TLX66 in SALA

TLX Ann: TLX66 Meets Study Objectives in Patients with AL Amyloidosis

TLX Ann: 1st Patient Dosed in Japanese Prostate Cancer Imaging Study

TLX Ann: German Distribution Agreement with Eckert and Ziegler

TLX Ann: App 3Y - issue of CEO options following Shareholder approval

TLX Ann: AGM Results of Meeting

TLX Ann: CEOs Address to AGM

Register to track TLX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC